Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5138 - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site

Urothelial Cancer


Kye Jin Park


Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239


K.J. Park

Author affiliations

  • Department Of Radiology, Asan Medical Center - University of Ulsan College of Medicine, 05507 - Seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5138


Reliable biomarkers to predict response to immunotherapy is crucial for patients’ counseling and decision making. This study was aimed to identify the role of CT radiomic features in predicting response to immunotherapy in patients with recurrent or metastatic urothelial carcinoma.


A total of 62 patients with their 224 lesions who underwent PD-1 and PD-L1 immunotherapy between March 2015 and November 2017 were retrospectively analyzed. The patients were temporally divided into training sets (n = 41; 155 lesions) and independent test set (n = 21; 69 lesions). For radiomics feature extraction, two radiologists independently segmented the region of interest at baseline CT on portal venous phase. A radiomics signature (RAD score) was built by using the least absolute shrinkage and selection operator (LASSO) method. The diagnostic performance of RAD score for prediction of response to immunotherapy was evaluated by C statistics.


The overall response rate of immunotherapy was 36.6% in the training set and 28.8% in the test set. RAD score revealed the C statistics of 0.83 (95% CI, 0.68–0.93) in the training set and a corresponding C statistics of 0.71 (95% CI, 0.48–0.89) in the test set.


This study suggests that radiomic features extracted from metastatic masses at baseline CT are predictive of response to immunotherapy in patients with recurrent or metastatic urothelial carcinoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.


Has not received any funding.


The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.